BioStock: SynAct Pharma announces oversubscribed share issue

In December, SynAct Pharma successfully completed directed issues raising 45 million SEK and now the rights issue linked to this transaction, raising approximately SEK 20 million, has been completed as well through an oversubscribed transaction conducted at a premium. The subscription rate was 161.8 per cent, thereby eliminating the need to activate guarantee commitments, underscoring strong shareholder support.

Read the full article at biostock.se:

https://www.biostock.se/en/2025/01/synact-pharma-announces-oversubscribed-share-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se